CD70 overexpression at diagnosis predicts relapse and supports dual CD19-CD70 CAR T-cell therapy in follicular lymphoma
Authors:
- Ferran Araujo-AyalaFAFerran Araujo-Ayala
- Maria RosMRMaria Ros
- Raluca AlexandruRARaluca Alexandru
- Judith Mateos-JaimezJMJudith Mateos-Jaimez
- Alba Rodriguez-GarciaARAlba Rodriguez-Garcia
- Marta Giménez-AlejandreMGMarta Giménez-Alejandre
- María Villalba-EsparzaMVMaría Villalba-Esparza
- Pablo MozasPMPablo Mozas
- Salut ColellSCSalut Colell
- Mireia BachillerMBMireia Bachiller
- Ferran NadeuFNFerran Nadeu
- 12 November 2026
- journal article
- Published by American Society of Hematology in Blood
- Vol. 148 (20) , 2511-2527
Abstract
Although first-line immunotherapy achieves remission in most patients with follicular lymphoma (FL), improved biomarkers and therapeutic strategies are required to identify and manage those who relapse. We investigated the immune microenvironment at diagnosis in uniformly treated patients with FL with extended follow-up (>11 years), comparing patients with relapsed disease and those with relapse-free disease. Transcriptomic profiling revealed the enrichment of inflammatory response pathways in relapsed patients, including cytokine overexpression and upregulation of CD70, a molecule implicated in immune activation and inflammation. Multiplex immunofluorescence confirmed CD70 overexpression at diagnosis in tumor cells as well as in CD8+ and CD4+ T follicular helper cells, correlating with inferior progression-free survival. Functional studies demonstrated that CD70+ tumor cells were more proliferative and induced CD70 expression in T cells, suggesting a feed-forward loop sustaining immune activation. To target these cells and enhance current chimeric antigen receptor (CAR) T-cell approaches, we engineered dual CD19-CD70 CAR T cells by cotransducing the CD19 CAR T-cell product ARI-0001 with a CD27-based anti-CD70 CAR. Dual CAR T cells exhibited enhanced in vitro cytotoxicity against patient-derived spheroids of FL, diffuse large B-cell lymphoma, and mantle cell lymphoma. In FL xenograft models, dual CAR T-cell treatment achieved superior disease control compared to monotargeted CAR T cells, inducing complete tumor clearance in the spleen and bone marrow. Collectively, these findings provide a strong preclinical rationale for the clinical development of CD19-CD70 dual CAR T-cell therapy to improve outcomes in high-risk FL and potentially other B-cell non-Hodgkin lymphomas.Keywords
This publication has 66 references indexed in Scilit:
- Efficacy and safety of the academic anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphomaHemaSphere, 2025
- Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviorsHematological Oncology, 2023
- Follicular lymphoma: The long and winding road leading to your cure?Blood Reviews, 2022
- Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphomaCancer, 2021
- CD27 expression on Treg cells limits immune responses against tumorsJournal of Molecular Medicine, 2021
- A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinomaCancer, 2019
- A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphomaInvestigational New Drugs, 2018
- First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70Cancer Chemotherapy and Pharmacology, 2015
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T CellsCancer Cell, 2015
- Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factorCell, 1993